Click Here to Register »

2018 Executive Sponsors

Adaptive Biotechnologies
Imaging Endpoints

2018 Associate Sponsors

BeiGene
Defined health

2018 Exhibitors

Axio Research
Caprion
Cytel
Intrinsic Imaging
KIYATEC Inc
Mitra Biotech
NeoGenomics
Personalis

2018 Supporting Partners

Trout Group

2018 Educational Partners

CIMT
CRI
SITC

2018 Media Partners

BioPharm Insight
BioPharma Dive
CanBiotech
Patient Empowerment
Pharmalicensing
Pharmaphorum
PharmaVOICE
Technology Networks

Event Blog


  • September 19, 2017

  • Pharma Talk Radio: Business Models for Complex Science by Dr Axel Hoos of GSK

    Originally presented during the business aspects plenary session at Immuno-Oncology 360° 2017, Dr Axel Hoos of GSK discusses business models for complex science. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. Dr Hoos returns as lead advisor, as well as moderating a talk called, “Investor Roundtable: The Role of IO […]

    Originally presented during the business aspects plenary session at Immuno-Oncology 360° 2017, Dr Axel Hoos of GSK discusses business models for complex science.

    Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. Dr Hoos returns as lead advisor, as well as moderating a talk called, “Investor Roundtable: The Role of IO within Large Pharma – Where Does it Stand?” with panelists from Citi, Atlas Venture, New Enterprise Associates, and SR One Ltd.

    Read More

  • September 18, 2017

  • Pharma Talk Radio: Increasingly Critical Role of Predictive Biomarkers in Cancer Immunotherapy

    Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the translational science and new technologies session from 2017’s Immuno-Oncology 360° conference. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.  

    Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the translational science and new technologies session from 2017’s Immuno-Oncology 360° conference.

    Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.

     

    Read More

  • September 1, 2017

  • Congratulations to IO360° Speaker Dr Jeff Legos and His Team at Novartis for the Early Approval for a New CAR-T Therapy to Treat ALL

    Congratulations to IO360° speaker Dr Jeff Legos and his team at Novartis for the early approval of Kymriah (tisagenlecleucel), the first CAR-T therapy to enter the market to treat acute lymphoblastic lymphoma. This has been recognized as a historic event by regulators. “We’re entering a new frontier in medical innovation with the ability to reprogram […]

    Dr Jeff Legos, Novartis

    Congratulations to IO360° speaker Dr Jeff Legos and his team at Novartis for the early approval of Kymriah (tisagenlecleucel), the first CAR-T therapy to enter the market to treat acute lymphoblastic lymphoma. This has been recognized as a historic event by regulators.

    “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA commissioner, Scott Gottlieb. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.”

    The first pediatric patient to ever undergo CAR-T therapy for ALL was Emily Whitehead, who received the treatment by CAR-T pioneer, Dr Carl June and his team at the Children’s Hospital of Philadelphia (CHOP). Emily and her parents, Tom and Kari Whitehead, joined IO360° 2016 to share the journey through the immunotherapy trial. Emily is now 5 years cancer-free and was present at the FDA advisory hearing in July, where the panel unanimously recommended that the agency approve the treatment. The early approval of Kymriah comes about a month ahead of the PDUFA date.

    John Carroll of Endpoints News, who will be speaking at the 2018 IO360°summit , provides a detailed update on the approval here.

    Dr Legos recently spoke at the IO360° 2017 program on integrating immune-oncology into cancer modalities. The next IO360° summit is on February 7-9, 2018 in NYC and includes a talk on “Target Discovery for CAR-Ts and TCRs” during the Discovery & Preclinical plenary session.

    Read More

  • August 23, 2017

  • Meet “The CheckPoints” – IO360° Speakers and IO Experts Perform to Further Research

    The CheckPoints, founded by IO360° speaker Dr Patrick Hwu, MD Anderson, is the Society of Immunotherapy of Cancer’s (SITC) house band and is comprised of cancer immunotherapy experts and researchers who perform to benefit the next generation of cancer research. You can watch these IO experts liven up the stage at SITC’s Presidential Reception at their annual conference in November and at the […]

    The CheckPoints, founded by IO360° speaker Dr Patrick Hwu, MD Anderson, is the Society of Immunotherapy of Cancer’s (SITC) house band and is comprised of cancer immunotherapy experts and researchers who perform to benefit the next generation of cancer research.

    You can watch these IO experts liven up the stage at SITC’s Presidential Reception at their annual conference in November and at the SITC networking event during the annual ASCO conference in June. The group is the official house band of SITC.

    Band members include IO360° speakers:

    – Dr Patrick Hwu, MD Anderson on keyboard

    – Dr Jason Luke, University of Chicago on trumpet

    – Dr Ferran Prat, MD Anderson on saxophone

    Additional band members include:

    – Dr James P. Allison, Johns Hopkins on harmonica

    – Dr Thomas F. Gajewski, University of Chicago on lead guitar

    – Dr Rachel W. Humphrey, CytomX on vocals

    – Brad Reinfeld, MD/PhD Student, Vanderbilt University on bass guitar

    – Dr Dirk Spitzer, Siteman Cancer Center on drums

    – Dr John Timmerman, UCLA Medical Center on guitar

    SITC is an educational partner for the 4th annual IO360° conference taking place February 7-9, 2018 at The Roosevelt Hotel, NYC.

    Read More

  • August 17, 2017

  • IO360° 2016 Keynote Dr Carl June’s Pioneering Work Called “Cancer’s Newest Miracle Cure” by Time Magazine

    Immuno-Oncology 360° 2016 keynote, Dr Carl June, Director of the Center for Cellular Immunotherapy at the University of Pennsylvania’s Abramson Cancer Center is making headlines again for curing a seven-year-old with Acute Lymphoblastic Leukemia (ALL) with CAR-T immunotherapy. Time Magazine called him “Cancer’s Newest Miracle Cure” for curing Kaitlyn Johnson, who was diagnosed at 18 months with ALL and had […]

    Immuno-Oncology 360° 2016 keynote, Dr Carl June, Director of the Center for Cellular Immunotherapy at the University of Pennsylvania’s Abramson Cancer Center is making headlines again for curing a seven-year-old with Acute Lymphoblastic Leukemia (ALL) with CAR-T immunotherapy. Time Magazine called him “Cancer’s Newest Miracle Cure” for curing Kaitlyn Johnson, who was diagnosed at 18 months with ALL and had spent several years going through multiple unsuccessful chemotherapy treatments. Her options were a bone-marrow transplant, where there was a good chance she would reject the donor cells, or participation in a gene therapy clinical trial.

    In 2015, Kaitlyn’s parents brought her to Dr June’s team at the Children’s Hospital of Philadelphia (CHOP), where she entered the immunotherapy trial and went through eight weeks of treatment and recovered. She has been in remission since.

    “This therapy is utterly transformative for this kind of leukemia and also lymphoma,” says Stephan Grupp, director of the cancer immunotherapy program at CHOP and one of the lead doctors treating patients in the study in which Kaitlyn participated.

    Dr Carl June with Emily Whitehead and her parents at IO360° 2016

    Dr Carl June is also known for treating Emily Whitehead, the first pediatric patient to undergo CAR-T Therapy, for ALL. Emily is now five years cancer-free. Emily’s parents, Tom and Kari Whitehead, joined IO360° 2016 to share her journey through the immunotherapy trial.

    The FDA is scheduled to make a decision in a matter of weeks on the recommendation provided by the FDA advisory panel which voted unanimously to move CAR-T therapy beyond testing and declare it a standard therapy for children with certain leukemias if all previous treatments failed.

    In 2016, Dr Carl June and Emily Whitehead’s parents spoke at IO360° about their experience. The next IO360° summit will take place on February 7-9, 2018 in New York City and will cover the full spectrum of IO research and development, from preclinical, translational and clinical to emerging technologies, business aspects, investor relations and trends in the field.

    Learn more about Emily Whitehead and the Emily Whitehead Foundation.

    Read More

  • August 15, 2017

  • The Trout Group and The Conference Forum Announce Immuno-Oncology 360° Partnership to Fight a Wider Range of Cancers

    The IO360° team at the Conference Forum to collaborate for the first time with the Trout Group on the 4th Annual Immuno-Oncology 360° Summit and IO360° TroutTalks KOL Series The Conference Forum and The Trout Group will collaborate for the first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The partnership culminates […]

    The IO360° team at the Conference Forum to collaborate for the first time with the Trout Group on the 4th Annual Immuno-Oncology 360° Summit and IO360° TroutTalks KOL Series

    The Conference Forum and The Trout Group will collaborate for the first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The partnership culminates with the 4th Annual IO360° Summit, to be held February 7-9, 2018, at The Roosevelt Hotel in New York City.

    “With our experience in producing the Immuno-Oncology 360° NYC event and The Trout Group’s expertise in investor relations, this is an exciting opportunity for us to work together on building IO programming specifically for the investor community,” said Kate Woda, Director, Immuno-Oncology 360°.

    On day three of the IO360° summit, The Trout Group Situation Room will feature fireside chats with IO biotech CEOs and executives, a panel discussion on “The Investor Lifecycle – How to Maneuver at Each Stage of Financing from Seed to Public Market,” and an IO CEO panel on “Checking the Target.”

    Day one and day two of IO360° have sessions covering business aspects and investor relations for the immuno-oncology community. Dr Andrew Baum, Head of Global Healthcare; Managing Director, Equity Research, Citi, will deliver a keynote evaluating and forecasting the IO space. Additionally, Dr Bruce Booth of Atlas Venture will discuss the venture capitalist perspective, and GSK’s Dr Axel Hoos will moderate an investor roundtable.

    Designed by lead advisors Dr Axel Hoos and Dr James Gulley, National Cancer Institute, the IO360° summit provides the most up-to-date research, data and progress to help IO stakeholders.

    Expanding on the IO360° summit’s programming, a series of IO360° TroutTalks have been created as part of the ongoing TroutTalks Key Opinion Leaders (KOL) Series, which features conversations with prominent and up-and-coming researchers who are driving scientific innovation. The first of these IO360° panels is on August 17, 2017 at The Trout Group’s annual Hamptons CEO Roundtable. Another panel will be held in January 2018 at J.P. Morgan’s Healthcare Conference in San Francisco. Panelists will be KOLs and IO industry experts addressing the most pressing topics and new research in the field.

    The IO360° panelists at the Hamptons CEO Roundtable include:

    • Dr Axel Hoos, SVP, Oncology R&D, GlaxoSmithKline
    • Dr Charles G. Drake, Director, Genitourinary Oncology, and Associate Director, Clinical Research, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center
    • Dr Adi Hoess, CEO, Affimed
    • Dr Garry Menzel, CEO, TCR²
    • Øystein Soug, CEO, Targovax

    Learn more about the Immuno-Oncology 360° Summit.

    Read More

  • August 14, 2017

  • Highlights from CRI on the 2nd Rational Combinations 360° 2017

    Source: Cancer Research Institute, August 11, 2017, by Arthur N Brodsky, PhD “Years ago, there was a lot of turnover [in my melanoma clinic] … new patients every six months. Now, [patients] are living years and years, getting to know their [own] families.” So began MD Anderson’s Patrick Hwu, MD, during his opening remarks at the […]

    Source: Cancer Research Institute, August 11, 2017, by Arthur N Brodsky, PhD

    “Years ago, there was a lot of turnover [in my melanoma clinic] … new patients every six months. Now, [patients] are living years and years, getting to know their [own] families.”

    Patrick HwuSo began MD Anderson’s Patrick Hwu, MD, during his opening remarks at the 2nd annual Rational Combinations 360° conference, which took place on June 28-29 at the New York Academy of Medicine. The meeting brought together clinicians, scientists, and industry experts from the leading organizations in oncology to discuss how best to build on the recent breakthroughs that have helped Dr Hwu’s patients and many others.

    These benefits are largely due to advances in immunotherapy, especially those involving checkpoint inhibitors. Additionally, over a dozen antibody-based immunotherapies have been approved, while cell-based immunotherapies (including CAR T cells), oncolytic viruses, and vaccines have also been effective and approved for certain cancers.

    However, immunotherapy by itself still doesn’t work for most patients with advanced cancer. To improve long-term survival for more patients with more cancers, it’s become clear that “combinations are the future,” but what remains unclear is which combinations work best for which patients. What’s needed—and what these experts assembled at the end of June to discuss—are smarter, safer, more rational strategies for combining the many available options.

    Essentially everyone agreed on the importance of biomarkers, and their power to provide superior diagnostic, prognostic, and therapeutic capabilities. There are more than 1,000 combinations currently being tested in the clinic, according to Dr Hwu, and by revealing important information—about tumors, immune cells, and their interactions—biomarkers can help doctors determine the most promising agents to combine and allow them to develop personalized treatment strategies that fit individual patients.

    Anne AssmusKenneth HanceTumoOliver Manzker antigens are one category of biomarker with incredible potential. These can include self-antigens, foreign antigens from viral infection, and neoantigens that arise from mutations. Some self-antigens are commonly overexpressed in a variety of cancer types, such as the growth-promoting HER2. Multiple anti-HER2 antibody-based immunotherapies have been approved for breast cancer (which commonly overexpress HER2) and gastroesophageal malignances, while other antibodies targeting self-antigens such as EGFR and CD20have also been approved for specific cancers. CAR T cells designed to eliminate CD19-expressing cancer cells have benefited leukemia and lymphoma patients as well as patients with multiple myeloma, according to Celgene’s Oliver Manzke, MD Additionally, several bi-specific antibodies with the ability to bind multiple targets—which were discussed by GlaxoSmithKline’s Kenneth Hance, PhD as well as Affimed’s Ann Assumus, PhD—appear promising against a range of cancers.

    Beyond these self-antigens, several experts suggested that mutated neoantigens may offer even greater opportunities for personalized immunotherapies. While tumors’ underlying mutations fuel their growth and progression, some of these mutations produce foreign neoantigens targetable by the immune system and immunotherapy, and patients whose tumors have increased levels of these immunogenic mutations are more likely to survive longer. Even though less than 1% of all mutations lead to these actionable targets, according to EMD Serono’s Laszlo Radvanyi, PhD, the more total mutations a tumor has accumulated, the likelier it is that some of these provide high-quality targets for immune cells.

    This helps explain why patients with heavily mutated tumors that are characterized by high microsatellite instability (MSI-H) and deficient DNA mismatch repair (dMMR) are associated with improved response rates to anti-PD-1/PD-L1 checkpoint immunotherapy. (Just recently pembrolizumab was approved for all patients—including children—with metastatic, MSI-H/dMMR solid tumors that don’t respond to other currently available treatments. This made it the first cancer treatment of any type to be approved for tumors regardless of their origin. Nivolumab has also been approved for colorectal cancer patients with MSI-H/dMMR tumors.)

    Notably, these MSI-H/dMMRH tumors are often—but not always—associated with the pre-existing activity of T cells as well as their presence in and around tumors (as captured by the Immunoscore), and these biomarkers have positive predictive value for patients with “hot” T cell-infiltrated tumors.

    jean pierre issaArjun BalarStephen_RussellUnfortunately the majority of patients have “cold” tumors that are neither highly mutated nor already engaged by killer T cells. For these patients, therapies have been developed to make their tumors more immunogenic, and thus more responsive to anti-PD-1/PD-L1 immunotherapy. Some approaches currently being used in the clinic are designed to increase the immunogenicity of tumors in an “antigen-agnostic” fashion. These include the potently oncolytic, RNA-based vesicular stomatitis virus (VSV) discussed by Stephen J Russell, MD, PhD, of the Mayo Clinic and Vyriad, a PARP inhibitor discussed by NYU Langone’s Arjun V Balar, MD, and epigenetic-targeting therapies discussed by Temple University’s Jean-Pierre Issa, MD

    Neil SegalIldiko CsikiImmunotherapies that target specific neoantigens were also discussed during the conference, such as the T cells engineered to target mutant KRAS G12D in colorectal cancer, which were highlighted by Memorial Sloan Kettering’s Neil H. Segal, MD, PhD Personalized DNA vaccines, which can educate immune cells about neoantigens and enable precise responses against these targets, represent another promising patient-specific approach. Inovio’s Ildiko Csiki, MD, PhD, described one such approach—their SynCon® technology—being used to design and manufacture DNA-based vaccines that can be administered non-invasively via the skin or muscle.

    With respect to these latter neoantigen-specific approaches (and to a lesser extent abnormally expressed self-antigens too), one challenge in particular involves identifying the most effective tumor-specific targets to incorporate into immunotherapies for individual patients because there are different types, some providing more useful targets than others for immunotherapy.

    Some come from “driver” mutations that fuel cancerous activity; others are “passenger” mutations along for the ride. While the more frequent “passenger” mutations provide more potential targets, they may also be more disposable than the rarer “driver” mutations. Furthermore, even when biopsies reveal the presence of patient T cells that already recognize a specific neoantigen, it doesn’t mean that the specific neoantigen is actually expressed on the surface of tumor cells.

    Christelle JohnsonPhil StephensSeveral tools with the potential to address these issues were showcased, including: FoundationOne®, which can help detect clinically relevant alterations (presented by Foundation Medicine’s Phil Stephens, PhD); and ACE ImmunoIDTM, which can help identify neoantigens and other relevant biomarkers (presented by Personalis’ Christelle Johnson, PhD). To complement these tools, predictive algorithm strategies are being refined and validated for neoantigen identification purposes, and should enable doctors’ to design more effective immunotherapy strategies for individual patients.

    Sharon BenzenoAlong with these improved immunotherapy approaches, biomarkers that allow doctors to determine a patient’s baseline immune activity (and any pre-existing adaptive immune responses) as well as monitor the development of any anti-tumor immune responses during tumors will also be beneficial. One example is the immunoSEQTM Analyzer (presented by Adaptive Biotechnologies’ Sharon Benzeno, PhD), which can characterize the frequency, density, and diversity of a patients’ T cell receptor (TCR) repertoire.

    Lisa ButterfieldDynamic biomarkers that capture the activity of dendritic cells (DCs) would also have immense value, given the central role of DCs in the formation of adaptive anti-tumor immune responses. University of Pittsburgh’s Lisa Butterfield, PhD, spoke about two especially important DC-associated phenomena—antigen loading and antigen spreading—for which biomarkers would be helpful.

    Additional immune-related biomarkers, such as those that capture macrophage behavior, could also help guide doctors’ treatment decisions and point them toward the combinations most likely to benefit an individual patient based on his or her specific tumor’s characteristics.

    To that end, doctors could benefit from technologies such as CANScriptTM (presented by Mitra Biotech’s Parker Cassidy), which uses biopsies to replicate a patient’s tumor environment—complete with tumor cells, immune cells, stromal cells, and vasculature.  With these models, doctors could gain even greater insight into which treatments work well for which types of tumors (and at which point during treatment). They could also allow the mechanisms of action for different treatments and/or combinations to be determined.

    Treatment-related toxicities are another area where biomarkers have the potential to improve patient care. In addition to developing biomarkers that can predict in advance whether a patient is likely to experience side effects or not, biomarkers monitored throughout the course of treatment could also help doctors recognize the signs of toxicities at their onset so that they can be more effectively mitigated and reversed.

    Hyam LevitskyAdi DiabJoyson KarakunnelIn addition to utilizing biomarkers for patient inclusion/exclusion in specific trials, Joyson Karakunnel, MD, FACP, of the Parker Institute for Cancer Immunotherapy and Arcus Biosciences, discussed the need to “unify the language” with respect to the toxicity management as well as the importance of standardizing dosing and scheduling protocols to improve consistency. Other toxicity-related issues that were brought up included the dynamics of toxicity, especially of the late-onset variety (by MD Anderson’s Adi Diab, MD) and the specific considerations for CAR T cell-associated toxicity (by Juno Therapeutics’ Hyam Levitsky, MD).

    Finally, several experts suggested other ways to make clinical trials more scientifically fruitful, financially efficient, and—most importantly—more beneficial for patients.

    Susan SlovinMerck’s Eric Rubin, MD, highlighted the benefits of “basket” and “umbrella” clinical trial designs. Baskets can include patients with multiple cancer types that are selected according to the chosen biomarker eligibility, while umbrellas can have multiple experimental arms that allow doctors to update the protocols based on early findings. Memorial Sloan Kettering’s Susan Slovin, MD, PhD, also discussed the benefits of this “adaptive” approach, which provides doctors with the added flexibility to adjust trial considerations in light of new developments, and could allow them to identify treatment-sensitive populations that might have been unknown at the beginning of the trial.

    Perhaps the most far-reaching and potentially beneficial suggestions came from David Wholley, of the Foundation for the National Institutes of Health, and MD Anderson’s Ferran Prat, PhD, JD, who shared their ideas on how to improve the field’s overall approach to clinical trials.

    david wholleyMr Wholley emphasized the NIH’s PACT effort, the goal of which is to support “robust, systematic, uniformly conducted clinical testing” of both already recognized biomarkers as well as those still in the exploratory phase, in order to generate a “better understanding of response and resistance” to combination immunotherapy treatment strategies.

    Ferran PratDr Prat began by pointing out the pitfalls of the current engagement model, before proposing an alternative way to conduct combination clinical trials in order to increase institutional engagement and decrease variability across sites. By focusing on the long-term (rather than the short term) and coordinated (rather than isolated) efforts, Dr Prat hopes that we can transform the current clinical trial model from one that is “fragmented and limited” into one that is “integrated and strategic”—and thereby better take advantage of the amazing potential of combination immunotherapies to benefit even more patients and save even more lives.

    Above all, the 2nd annual Rational Combinations 360° conference provided hope for the future. While the challenges cancer presents remain formidable, it’s clear that our strategies for treating cancer are getting more sophisticated and formidable as well. Recent breakthroughs have dramatically enhanced survival for many cancer patients. As more is learned about the relationship between cancer and the immune system, and as we learn to more effectively combine immunotherapy with other treatments, that trend is likely to continue.

    As part of the effort to ensure that it does continue, many of these same experts and others will reconvene February 7-9, 2018, at the Roosevelt Hotel in New York City at the Conference Forum’s Immuno-Oncology 360° conference. 

    CRI is an educational partner for both the 4th annual Immuno-Oncology 360° and the 2nd annual Rational Combinations 360°.

    Read More

  • August 10, 2017

  • Expert Citi Analyst Dr Andrew Baum to Deliver Keynote at IO360° in February 2018

    We are delighted to announce that Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research, Citi, will be the keynote speaker on the Investor Relations in Immunotherapy Plenary Session at the 4th annual Immuno-Oncology 360° program on February 7-9, 2018. Dr Baum’s keynote will provide an in-depth evaluation and forecast of the immuno-oncology (IO) […]

    We are delighted to announce that Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research, Citi, will be the keynote speaker on the Investor Relations in Immunotherapy Plenary Session at the 4th annual Immuno-Oncology 360° program on February 7-9, 2018. Dr Baum’s keynote will provide an in-depth evaluation and forecast of the immuno-oncology (IO) space. He will also share his perspective as part of an investor roundtable on the role of IO within large pharma.

    Dr Baum has a deep strategic insight into the global healthcare value chain, as well as a broad network of contacts throughout the industry. He was one of the earliest commentators to highlight to investors the deep structural deficiencies of the historic operating structure and the need to evolve towards a radically different model.

    “IO360° continues to help the IO community stay at the forefront of the most relevant research and developments by featuring industry experts, such as Dr Baum, who have their fingers on the pulse of cancer immunotherapy,” says conference director Kate Woda. “As the keynote on the investor relations plenary session, Dr Baum’s insight will help to foster collaboration between the different parties working in all aspects of cancer immunotherapy.”

    The next IO360° summit will take place on February 7-9, 2018 in New York City and will cover the full spectrum of IO research and development, Including preclinical, translational, clinical, emerging technologies, business aspects, investor relations and trends in the field.

    Read More

  • July 31, 2017

  • Fostering Collaboration at IO360° 2018 Across All Immuno-Oncology Stakeholders

    The 4th annual NYC Immuno-Oncology 360° (IO360°) conference (February 7-9, 2018) offers attendees the most exposure to the entire spectrum of the IO R&D ecosystem. Over the course of three days, the program will address immunotherapy approaches and novel data from discovery to translational and clinical, as well as emerging technologies, business aspects, investor relations, […]

    The 4th annual NYC Immuno-Oncology 360° (IO360°) conference (February 7-9, 2018) offers attendees the most exposure to the entire spectrum of the IO R&D ecosystem. Over the course of three days, the program will address immunotherapy approaches and novel data from discovery to translational and clinical, as well as emerging technologies, business aspects, investor relations, trends and collaborations in the field.

    IO360° provides an opportunity for stakeholders from all aspects of IO to gather to discuss the most current data, innovative approaches and complexities of IO that are changing the way cancer is treated,” said Kate Woda, Conference Director.

    This year’s meeting includes new plenary sessions to ensure all stakeholders benefit from the comprehensive 360° overview of IO developments. Day one features the new Investor Relations in Immunotherapy Plenary session with a keynote address presented by expert analyst Dr Andrew Baum, Citigroup, followed by a deeper look into the IO venture space with Dr Bruce Booth, Atlas Venture, Dr Ali Behbahani, NEA, and Dr Simeon George, SR One.

    On day two, the Trends and Collaborations Plenary session introduces industry reports delivered by BioCentury and Endpoint News as a starting point for discussions on a year in review on IO developments and future outlook. A special focus will be dedicated to The Cancer Moonshot Progress delivered by Greg Simon, Director of the Biden Cancer Initiative and Former Executive Director of the Former White House Cancer Task Force.

    To encourage collaboration, IO360° has dedicated a full plenary session toward Emerging Technologies and Innovative Solutions where attendees will have the opportunity to learn more about technologies and solutions that will help advance developments for providing treatment to cancer patients. This session also includes a Biotech Showcase where investors and large pharma seeking innovative sources to contribute to their IO pipeline can learn more about new and emerging immunotherapy assets from novel IO biotech companies.

    Also new to the program is the Trout Group Situation Room Plenary session on day three that includes fireside chats with IO biotech CEOs, an investor lifecycle panel focusing on how to maneuver at each stage of financing from seed to public market, and a CEO panel on checking the target.

    “In working with our lead advisors Dr Axel Hoos and Dr James Gulley on the development of  the 2018 program, we wanted to ensure there are valuable opportunities for everyone involved in IO to benefit from,” said Ms. Woda.

    Throughout the entire conference, there are numerous possibilities for networking, as well as dedicated times for one-on-one partnering meetings. All breaks will be held in the exhibition hall where attendees can meet with organizations that provide tools and resources which may be helpful in supporting and advancing their IO pipelines. There will also be small, numbered tables during the conference level, which attendees can reserve for one-on-one meetings in advance or onsite via the Trout Group partnering software tool.

    “Cancer immunotherapy developments are advancing at a rapid pace along a bumpy road and it is important to provide attendees with a forum, where they can learn about new approaches and cutting-edge strategies that will help revolutionize the way cancer is treated,” said Ms. Woda. “IO360° brings together all stakeholders involved in IO and gives them additional opportunities to connect and collaborate on finding ways to fight a wider range of cancers.”

    Read More

  • July 13, 2017

  • IO360° Speakers, The Whitehead Family, Meet with FDA on a New Treatment for Leukemia

    Emily Whitehead, 12,  joined her parents Tom and Kari Whitehead, on Tuesday in Washington, D.C. at a hearing for the FDA about a new treatment for leukemia. Emily was the first patient to receive this treatment and as you can see in the photo, is doing great. We want to thank the Whiteheads for their relentless advocacy […]

    Emily Whitehead, 12,  joined her parents Tom and Kari Whitehead, on Tuesday in Washington, D.C. at a hearing for the FDA about a new treatment for leukemia. Emily was the first patient to receive this treatment and as you can see in the photo, is doing great. We want to thank the Whiteheads for their relentless advocacy to help get this treatment to patients faster. The Whiteheads spoke at the IO360 conference in NYC. 

    An FDA  panel  recommended that the agency approve the first treatment that genetically alters a patient’s own cells to fight leukemia. This treatment powerfully boosts the immune system to shut down the disease.

    If the FDA accepts the recommendation, which is likely, the treatment will be the first gene therapy to reach the market. Novartis is in the running to be the first, and it is working on similar types of treatments for another type of leukemia, as well as multiple myeloma and an aggressive brain tumor.

    Congratulations to all!

    For more info about the IO360 conference, click here.

    Read More

  • June 15, 2017

  • Rational Combinations 360° Educational Partner Hosts 5th Annual Cancer Immunotherapy Month in June

    Cancer Immunotherapy Month, organized by The Cancer Research Institute (CRI), occurs every June and aims to increase public awareness of cancer immunotherapy, clinical trials and research to help make curing cancer a reality. “Advances in immunotherapy research have brought us to a tipping point in the transformation of cancer treatment,” said Dr Jill O’Donnell-Tormey, IO360° […]

    Cancer Immunotherapy Month, organized by The Cancer Research Institute (CRI), occurs every June and aims to increase public awareness of cancer immunotherapy, clinical trials and research to help make curing cancer a reality.

    “Advances in immunotherapy research have brought us to a tipping point in the transformation of cancer treatment,” said Dr Jill O’Donnell-Tormey, IO360° speaker and CEO/director of scientific affairs at CRI. “But these advances have created an urgent need to equip cancer patients and their caregivers with knowledge about immunotherapy so that they can make the most informed decisions when discussing their treatment options with their oncologists.”

    As part of Cancer Immunotherapy Month, CRI—along with Rational Combinations 360° educational partner, Society of Immunotherapy of Cancer (SITC)—host several educational programs to help raise awareness. Other cancer research organizations also support this effort by hosting their own programs.

    CRI’s Chairman of the Cancer Immunotherapy Consortium, Dr Axel Hoos, GSK, along with Dr Patrick Hwu, MD Anderson, and Dr Ian McCaffery, Corvus Pharma, present the 2nd annual Rational Combinations 360° program addressing business, clinical and scientific advancement in IO combination strategies to fight a wider range of cancers, June 28-29 in NYC.

    Learn more about Rational Combinations 360°.

    View CRI’s Cancer Immunotherapy Month Calendar.

    View SITC’s Cancer Immunotherapy Month Calendar.

    Read More

  • May 10, 2017

  • The Conference Forum Attends Dance Against Cancer 2017 with Friends

    The Conference Forum was one of the proud sponsors of the 7th annual Dance Against Cancer, which featured world premiere dance performances, on May 8th at the AXA Equitable Theater. Joining us were friends from GSK, BMS and Memorial Sloan Kettering. All proceeds from this event benefit cancer research that the American Cancer Society funds in New […]

    Onalee Smith (The Conference Forum), Dr Axel Hoos (GSK) & guest, Valerie Bowling (The Conference Forum), Dr Chung-Han Lee (Memorial Sloan Kettering) & Yu-Lun Chiu, and Elizabeth Bard (The Conference Forum)

    The Conference Forum was one of the proud sponsors of the 7th annual Dance Against Cancer, which featured world premiere dance performances, on May 8th at the AXA Equitable Theater. Joining us were friends from GSK, BMS and Memorial Sloan Kettering.

    All proceeds from this event benefit cancer research that the American Cancer Society funds in New York City and beyond, and will support patient service programs like Hope Lodge New York City, which provides free lodging to cancer patients who need to travel to New York for treatment. Announced during the performance was the exciting news that since its inception, Dance Against Cancer has raised over $1,000,000 in support of the American Cancer Society.

    Valerie Bowling (The Conference Forum), Mary Christian (BMS), Dr Julie Hambleton (BMS), and Elizabeth Bard (The Conference Forum)

    Dance Against Cancer was founded in 2010 by Daniel Ulbricht, principal dancer at New York City Ballet, and Erin Fogarty, Director of Programming at Manhattan Youth Ballet, after they both lost family members to cancer. This year’s lineup included performances by members of New York City Ballet, American Ballet Theatre, Alvin Ailey American Dance Theater, Miami City Ballet, Dance Theatre of Harlem, Ballet Met and more. Every dancer and choreographer dedicated their work to loved ones they lost to cancer or who are battling this disease. It was inspiring to see the performing arts world contribute to the world of science and patient support through their amazing talents.

    The Conference Forum is the organizer of the Immuno-Oncology 360° and Rational Combinations 360° conferences, so it is especially an honor to be part of a community that brings performing arts to help fight cancer.

    Read More

  • May 3, 2017

  • Rational Combinations 360° & IO360° Lead Advisor, Dr Axel Hoos, GSK Speaks on Prioritizing Immunotherapy Combinations

    Dr Axel Hoos, SVP, Oncology R&D, GSK, shares his insights on the drivers behind prioritizing combinations in order to have the most transformation effect for cancer patients in a video interview with Dr James Gulley, NCI and Valerie Bowling, Immuno-Oncology 360° (IO360°). “The breadth of modalities, what we have today, is enormous,” said Dr Axel Hoos, SVP, […]

    Dr Axel Hoos, SVP, Oncology R&D, GSK, shares his insights on the drivers behind prioritizing combinations in order to have the most transformation effect for cancer patients in a video interview with Dr James Gulley, NCI and Valerie Bowling, Immuno-Oncology 360° (IO360°).
    “The breadth of modalities, what we have today, is enormous,” said Dr Axel Hoos, SVP, Oncology R&D, GSK in an earlier interview with Valerie Bowling. “There is a lot of opportunity arising from it. It also brings complexity. The maximum value of different modalities will most likely come from combining them,” said Dr Hoos in an earlier interview with Bowling.

    Dr Hoos will be co-chairing and moderating a partnership panel at the 2nd annual Rational Combinations 360°, taking place June 28-29, 2017 at The New York Academy of Medicine, NYC. The program, led by industry and academic leaders, addresses scientific, clinical and business developments in IO combination strategies to fight a wider range of cancers.

    Click to Watch Video

     

    More information on Rational Combinations 360°.
    Learn more about Immuno-Oncology 360°.

    Read More

  • April 26, 2017

  • The Conference Forum Proudly Sponsors Dance Against Cancer 2017

    The Conference Forum is proud to sponsor, for the second time, Dance Against Cancer on May 8th at the AXA Equitable Theater with world premiere dance performances. All proceeds from this event will benefit lifesaving cancer research that the American Cancer Society funds in New York City and beyond, and will support patient service programs like Hope […]

    The Conference Forum is proud to sponsor, for the second time, Dance Against Cancer on May 8th at the AXA Equitable Theater with world premiere dance performances. All proceeds from this event will benefit lifesaving cancer research that the American Cancer Society funds in New York City and beyond, and will support patient service programs like Hope Lodge New York City, which provides free lodging to cancer patients who need to travel to New York for treatment.
    Dance Against Cancer
    This year’s lineup includes performances by members of New York City Ballet, American Ballet Theatre, Alvin Ailey American Dance Theater, Miami City Ballet, Dance Theatre of Harlem, Ballet Met, NYC’s Broadway community, ballroom and more.

    The Conference Forum is the organizer of the Immuno-Oncology 360° and Rational Combinations 360° conferences, so it is especially an honor to be part of a community that brings performing arts to help fight cancer.

    Founded in 2010 by Daniel Ulbricht, principal dancer at New York City Ballet, and Erin Fogarty, Director of Programming at Manhattan Youth Ballet, after they both lost family members to cancer. Dance Against Cancer has raised over $825,000 in support of the American Cancer Society. The event will showcase the works of Larry Keigwin, Christopher Wheeldon, James Whiteside, Marcelo Gomes, Frederick Earl Mosley, Edwaard Liang, Darrell Grand Moultrie, Josh Prince’s Broadway Dance Lab and five world premieres, created specifically for Dance Against Cancer.

    Read More

  • April 18, 2017

  • New Immunotherapy Drug Approved to Treat Non-Small Cell Lung Cancer

    Merck’s SVP of Clinical Global Development, Dr Roy Baynes, and BMS’s VP, Head of US Medical and R&D, Dr Julie Hambleton will be sharing data on combination immunotherapy for Lung Cancer and emerging key combinations with pembrolizumab in late stage development at the 2nd annual Rational Combinations 360° program, June 28-29, in NYC. Roche’s Tecentriq® (atezolizumab) […]

    Merck’s SVP of Clinical Global Development, Dr Roy Baynes, and BMS’s VP, Head of US Medical and R&D, Dr Julie Hambleton will be sharing data on combination immunotherapy for Lung Cancer and emerging key combinations with pembrolizumab in late stage development at the 2nd annual Rational Combinations 360° program, June 28-29, in NYC.

    Roche’s Tecentriq® (atezolizumab) joins BMS’s Opdivo® (nivolumab) and Merck’s Keytruda® (pembrolizumab) in treating certain patients with non-small cell lung cancer (NSCLC).

    Roche received approval on Monday, April 17, 2017 to expand it’s use to treat patients with metastatic non small cell lung cancer (NSCLC) who are not eligible for standard cisplatin chemotherapy.

    Atezolizumab was first approved in May 2016 for treating certain patients with urothelial carcinoma. With the expanded use approval, this now means there are three FDA approved immunotherapy treatment options for NSCLC.

    Access the full press release.
    Learn more about the 2nd annual Rational Combinations 360° program.

    Read More

  • February 9, 2017

  • 3rd Annual Immuno-Oncology 360° Led by Dr Axel Hoos (GSK) and Dr James Gulley (NCI)

    A 360-degree approach addressing business aspects, clinical advancements and scientific data to transform the way cancer is treated. The 3rd annual Immuno-Oncology 360° (IO360) event took place February 1-3, 2017 in NYC. Designed by lead advisors Dr Axel Hoos (GSK) and Dr James Gulley (NCI), the program provided a unique 360-degree approach addressing the most-up-to-date […]

    A 360-degree approach addressing business aspects, clinical advancements and scientific data to transform the way cancer is treated.

    The 3rd annual Immuno-Oncology 360° (IO360) event took place February 1-3, 2017 in NYC. Designed by lead advisors Dr Axel Hoos (GSK) and Dr James Gulley (NCI), the program provided a unique 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that helped to accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated.

    Day one’s plenary sessions covered “Preclinical Science,” chaired by Dr Patrick Mayes, Director & Early Development Leader, GlaxoSmithKline and “Translational Science and New Technologies,” chaired by Dr Renee Donahue, Scientist, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute. Highlights include:

    1.    Can Agonist Antibodies Play a Role in Immunotherapy?

    Though the concept of incorporating agonist antibodies into an immunotherapeutic treatment regimen is still a long way from durable viability, Dr Mayes shared that there is at least some reason for optimism.
    “We believe that immune agonist antibodies have some significant potential and promise as cancer therapies, and I think that’s been illustrated by the explosion of agents that have entered the field in the last five years.”

    Dr Mayes said developing agonist antibodies for immunotherapy presents a number of unique challenges, one of which being the elevated need for precise dose selection. “Dose level is critical when it comes to these agents,” he said. “It’s not about dosing high, it’s about finding the right dose level to achieve significant activation.”

    Another issue limiting the development of viable agonist antibodies is the degree to which FcyR and IgG interactions differ between animal and human test subjects, which Dr Mayes said complicates the translation of functional data.
    “It means that interpretations that we’re able to make in a mouse system or even a monkey system aren’t necessarily going to translate, since the IgG specifically is such an important characteristic for agonist antibodies. We need to be very careful about how we interpret our data.”

    2.    Sequencing of Combination Agents

    Another emerging concept highlighted in several presentations on Wednesday was the combination of immunotherapy with certain types of chemotherapy, despite their inherent contradiction in function.
    “It’s actually not as bad an idea as some might think,” said Dr Charles Drake, director of genitourinary oncology and associate director for immunotherapy at the Columbia University Medical Center’s Herbert Irving Comprehensive Cancer Center.

    Dr Drake noted there is a growing body of research that suggests the addition of chemotherapy to a regimen of immunotherapeutics can improve the overall efficacy of the treatment. Exactly how successful the tactic can be may depend on how carefully timed the integration of therapies is on a repeatable basis. “Research shows that if you introduce an anti-PD1 during the initial antigen encounter right at the time the T-cell sees its target antigen, you can actually reprogram that T-cell to continue having an effect or a function further down the line, and can actually see longer survival as a result.”

    3.    Immunosequencing in Cancer Treatment

    Dr Lanny Kirsch, SVP, Translational Medicine, Adaptive Biotechnologies, said his focus has been refining and expanding the application of immunosequencing in cancer treatment.
    “In order to expand the benefit of immunotherapy to the greatest number of patients, it would be extremely useful to be able to assess the immune status of a patient and the tumor that resides inside of them. Immunosequencing is one approach to doing that. It’s the enumeration, specification and quantification of each and every B or G cell in any biological sample.”

    Dr Kirsch also shared that he is particularly interested in the prospect of using immunosequencing to develop blood-borne biomarkers that could more accurately track the effects of an immunotherapy, rather than relying on biopsied tissue.
    “We think that could be of significant use in the care of patients receiving immunotherapy.” “We hope we’re becoming more refined and sophisticated in terms of being able to apply a computational matrix to better extract critical information from these kinds of analyses,” Kirsch later added.


    Day two featured plenary sessions on “Trends & Collaborations in the IO Space,” chaired by Dr Ramy Ibrahim, VP and Head of R&D, Parker Institute for Cancer Immunotherapy, “Clinical Advancements Part 1,” chaired by Dr James Gulley, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute and “Imaging Methodologies & Techniques for Immunotherapy,” chaired by Dr Andrea Perrone, Associate Vice President, Translational Medicine, Merck Research Labs. Key takeaways from day two include:

    1.    New Details on FNIH’s Forthcoming Partnership for Accelerating Cancer Therapies

    In 2016, the Foundation for the National Institutes of Health announced plans to develop a new program under the Cancer Moonshot initiative, noting at the time the lack of cohesion within the industry when it came to generating and managing clinical data.
    “We have a lot of knowledge gaps and duplicative deployment of resources, and I think we could probably do much better with a much more systematic and uniform approach, particularly in the area of biomarker development,” said David Wholley, MPhil Director, Research Partnerships Division, FNIH.

    Mr Wholley hopes to eliminate those disconnects and redundancies with the launch of FNIH’s Partnership for Accelerating Cancer Therapies (PACT), which he said will establish a network of core laboratories to conduct, standardize and validate biomarker assays.
    “We decided to focus our efforts on a problem that was urgent for everyone, but also tractable and highly relevant to the types of resources that NCI was already developing. The focus here is building out a more systematic and robust effort to develop and validate biomarkers for immunotherapy and, particularly, combination trials.” Assuming a successful fundraising campaign, the PACT is expected to launch in the third quarter of 2017. The partnership’s other primary objectives will include:

     – Funding the development of new exploratory biomarkers and assays
     – Incorporating biomarker modules into trials
     – Creating a comprehensive database of biomarker module and clinical data

    2.    Clinical Advancements and Challenges

    Dr Roy Baynes, SVP and Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories, provided an update on expanding the approved monotherapeutic uses of PD-1 antibodies in the treatment of various cancers.
    “As we look at the goal of trying to establish PD-1 as being transformational in cancer, I believe we are making fairly good progress,” Dr Baynes said.
    Having already established its PD-1 antibody Keytruda as a standard-of-care monotherapy for advanced melanoma, Dr Baynes said Merck recently achieved global approval for PDL-1 high front-line and PDL-1 positive second-line lung cancer patients. The company has also gained approval for its PD-1 antibody in the treatment of head and neck cancer, and is under priority review for indications within Hodgkin’s Lymphoma and MSI-H cancer. Additionally, Dr Baynes said Merck is exploring recent positive clinical outcomes in the treatment of first- and second-line bladder cancer.

    Dr Baynes also participated in a panel discussion moderated by Dr Gulley, also including Dr Alessandra Cesano, Chief Medical Officer, nanoString Technologies, Dr Patrick Hwu, Head, Division of Cancer Medicine/ Department Chair, Melanoma Medical Oncology/ Department Chair, Sarcoma Medical Oncology, MD Anderson Cancer Center and Robert Millham, MS, MSc, PharmMed SVP & General Manager, Hematology & Oncology, inVentiv Health. The panel focused on key clinical challenges facing the IO field and addressed increasing the rate of patient responses to immunotherapy, refining the field’s approach to combination therapies, reducing the risk of toxicity in combination trials and establishing a uniform system of generating, collecting and managing clinical data.

    3.   New Modifications to RECIST 1.1 for Immunotherapeutics

    Dr Elisabeth de Vries, Professor, Medical Oncology, University Medical Centre Groningen, outlined the RECIST Working Group’s recommendations for a new guideline for imaging data collection and management in clinical immunotherapy trials, dubbed iRECIST.
    “The rationale for developing iRECIST was the fact that we know that there is an atypical pattern of response in multiple immunotherapy trials, but the true frequency is unknown,” Dr de Vries said. “We also know that there are different interpretations of immune response criteria across trials, which makes it very difficult to compare the trials.”

    Primary among the changes proposed under the iRECIST guideline is the difference in time point response after a RECIST 1.1 progressive disease identification. The first RECIST 1.1 progressive disease would be termed an “unconfirmed” progressive disease and must be confirmed at the next assessment 4-8 weeks afterward. Also, the time point for tumor response would be dynamic and based on a change from baseline or from nadir, as well as the last I-response. Dr de Vries said the full iRECIST guideline will be published later this year in Lancet Oncology. Dr Patricia Keegan, Director, Division of Oncology Products 2 (DOP2), OHOP, OND, CDER, FDA, said the FDA will continue to use RECIST 1.1 as the primary criteria for tumor-based endpoint imaging, but that she was “very eager to see how this plays out, in terms of whether this criteria or something based on it, would provide better information and better correlate to clinical outcomes.”


    Day three concluded the conference with plenary sessions, “Business Aspects of Immuno-Oncology,” chaired by Mark Simon, MBA, Partner, Torreya Partners and “Clinical Advancements Part 2,” chaired by Dr Jeffrey Legos, SVP, Oncology Global Development & Medical Affairs, Novartis Pharmaceuticals.

    1.    Improving Patient Experiences in Clinical Trials

    Based on his own experiences finding, joining and completing clinical trials in immunotherapy, T.J. Sharpe’s (Melanoma Survivor, Patient Advocate and Cancer Blogger) keynote address implored physicians in the IO field to find ways of making the clinical trial process easier for patients. Diagnosed with Stage 4 melanoma in August 2012, Mr Sharpe said he only knew to inquire about the possibility of joining a clinical trial because of prior professional experience and a network of contacts in the pharmaceutical industry.
    “Patients don’t always know to look for different treatments, particularly immunotherapy trials. I was able to find a trial because I had a lot going for me.”

    Though grateful for the PD-1 treatments that to-date have aided in an 85% reduction in measurable tumor burden, T.J. said the process of obtaining those treatments is fraught with complexity and bureaucracy, which many cancer patients may find discouraging or prohibitively difficult to navigate.
    “It might just be a document to you, but it’s my life,” Sharpe said. “The average contract for a clinical trial takes about 18 weeks to execute. That’s more than 3,100 melanoma patients who will die the next time a contract goes from beginning to end. I know we can’t save all of them, but how many T.J.’s are out there trying to get into your trial to try your new therapy and are waiting for a piece of paper to be signed?”

    2.   The Growing Need for New Reimbursement Models

    As public and political pressures mount on the pharmaceutical industry over the rising cost of specialty drugs, it is critical that the industry work with healthcare payers and providers to develop new reimbursement models for high-cost curative therapies, according to Dr Lindee Goh, Partner at Tapestry Networks.
    “Developing a drug isn’t very helpful if there isn’t market access to that drug,” Dr Goh said. “If patients can’t get it because they can’t afford it, then the innovation is wasted and patient lives are left at risk.”

    Dr Goh outlined several potentially sustainable reimbursement models that could ease the financial pressure on patients, including rebates, amortization, payer-backed annuities, reinsurance and government-issued bonds. However, reaching a consensus on new systems of reimbursement will require a concerted and collaborative effort among stakeholders in the healthcare industry, considering the multitude of regulatory, political and economic challenges that must be addressed.
    “There’s been a lack of leadership across the stakeholder groups,” Dr Goh noted. “There isn’t any clear industry champion saying that they want to change the model, and there’s a lot of political downside to being a lead in this area.”

    3.    Talent Management Issues in the IO Space

    Adam Millinger, Founding Partner, ProMotion Career Management, described the competition for talent in the IO field as an “arms race” fueled not only by a shortage of qualified candidates, but also systemic shortfalls in talent management strategies within the industry.
    “It will come as no surprise that there’s a big gap between supply and demand for talent. [The IO space] is a new area, and as much as people are being trained, there just aren’t enough folks out there at the moment,” Mr Millinger said. “What you also have is the group that rode in on the early wave of IO that are now extremely senior within the industry, and the less-seasoned people coming in aren’t able to fill that mid-level gap.”

    Mr Millinger noted other contributing factors to the IO field’s talent shortage include a reticence among traditional oncologists to learn a new discipline and companies’ weakened ability to negotiate salaries and titles with those who do have the requisite experience. As difficult as the competition for qualified talent can be, Mr Millinger thinks the industry’s larger problem appears to be retaining the talent they are able to attract, due primarily to a misalignment of motivations among new hires and executive-level management, as well as a lack of proactive career development and succession planning.
    “For the people in the trenches doing the work, there’s a strong feeling that IO is a harsh, unforgiving space where companies are really pushing people to their stress limits,” Millinger said. Executives, on the other hand, are stuck in a “mercenary mindset, where they think that people who do have the experience are taking advantage and chasing titles and paychecks.” “There needs to be a better alignment of people and motivations to actual outcomes,” he added.

    The Conference Forum will present the next program in the IO space, the 2nd annual Rational Combinations 360°, on June 28-29, 2017, at The New York Academy of Medicine in New York City. Designed by lead advisors Dr Axel Hoos (GSK), Dr Ian McCaffery (Corvus Pharmaceuticals) and Dr Patrick Hwu (MD Anderson), #IOCombos360 provides the most up-to-date progress on combination developments from business aspects, clinical advancements and scientific data that will help prioritize the best cancer treatments for individual patients and tumor types. Register here.

    Save the date for 4th Annual Immuno-Oncology 360° in NYC, to be held February 7-9, 2018, in NYC.

    Read More

  • January 17, 2017

  • Conference Forum Presented Immuno-Oncology Panel Discussion During the JP Morgan HealthCare Conference

    The Conference Forum was delighted to work with a group of leaders in the field of immuno-oncology on a panel focused on Filtering the Hype for the Next Wave of Targets during the JP Morgan Healthcare conference. Axel Hoos, MD, PhD, SVP Oncology R&D, GSK and Co-Chair, IO360 Ira Mellman, PhD, VP, Cancer Immunology, Genentech Lindee Goh, Partner, […]

    The Conference Forum was delighted to work with a group of leaders in the field of immuno-oncology on a panel focused on Filtering the Hype for the Next Wave of Targets during the JP Morgan Healthcare conference.

    AxelHoos_color
    Axel Hoos, MD, PhD, SVP Oncology R&D, GSK and Co-ChairIO360

    Mellman_Ira-web
    Ira Mellman, PhD
    , VP, Cancer Immunology, Genentech

    Goh_Lindee-web
    Lindee Goh
    , Partner, Tapestry Networks

    Hamid_Omid-web
    Omid Hamid, MD
    , Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic

    ramyibrahim-blog
    Ramy Ibrahim, MD
    , VP and Head of R&D, Parker Institute for Cancer Immunotherapy

    IOJPMpanelKey topics addressed included next-generation I/O therapeutics, check point inhibitors, biomarker strategies, coordinating across industry for better approaches to demonstrate value, the future of combinations, the need for high value investigations, challenges with disease modifying medicines, different pathways of costs and coverage for personalized medicine and more. The panel was moderated by Querida Anderson, Editor-in-Chief, BioPharm Insight. After the panel, BioPharm Insight hosted a packed-out reception which took place early evening on January 9th  at the Chandran Art Gallery in San Francisco. If you missed the panel, the Conference Forum is presenting the IO360 conference with over 50 leaders in immuno-oncology on February 1-3 in NYC. For more information, click here.

    Huge thanks to all the panelists, Kate Woda for organizing the panel and our friends at BioPharm Insights for a great job on the overall event.

    Read More

  • January 9, 2017

  • Announcing Immuno-Oncology KOL Panel at the JPM Health Week in San Francisco

    We are pleased to announce that the IO360 team at the Conference Forum together with BioPharm Insight are co-presenting a panel discussion on Immuno-Oncology: Filtering the Hype for the Next Wave of Targets along side the JP Morgan HealthCare conference. The panel discussion will take place January 9, 2017 at the Chandran Art Gallery in San Francisco. […]

    We are pleased to announce that the IO360 team at the Conference Forum together with BioPharm Insight are co-presenting a panel discussion on Immuno-Oncology: Filtering the Hype for the Next Wave of Targets along side the JP Morgan HealthCare conference. The panel discussion will take place January 9, 2017 at the Chandran Art Gallery in San Francisco. Following the discussion, there will be a networking reception.

     

    Panel Discussion: 5:30 – 6:30 pm

    Immuno-Oncology: Filtering the Hype for the Next Wave of Targets

    Key opinion leaders (KOLs) and industry experts address timely issues in the immuno-oncology field including, but not limited to next-generation I/O therapeutics, check point inhibitors, combinations, pricing and reimbursement expectations, and more.

     

    Panelists:
    Axel_Hoos_new_bw

    Axel Hoos, MD, PhD
    SVP Oncology R&D, GSK and Co-Chair, IO360

     

     

     

    ira-mellman-bw

    Ira Mellman, PhD
    VP, Cancer Immunology, Genentech

     

     

     

    lindee-goh-gw

    Lindee Goh
    Partner, Tapestry Networks

     

     

     

    Omid Hamid BW

    Omid Hamid, MD
    Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic

     

     

    Ramy_Ibrahim_bw

    Ramy Ibrahim, MD
    VP and Head of R&D, Parker Institute for Cancer Immunotherapy

     

     

     

    Moderated by:
    querida_anderson_bw

     

    Querida Anderson
    Editor-in-Chief, BioPharm Insight

     

    Reception 6:30 – 8:30 pm

     

    Registration
    This is a complimentary limited seating event. RSVP is required. To register, please click here.

     

    Venue Information
    chandaran-art-gallery-400-x-171Chandran Art Gallery
    459 Geary Street
    San Francisco, CA 94102

     

     

     

     

     

    * Please note, the panel portion of the event is expected to sell out so register quickly. More attendance will be open for the networking portion of the event.

     

    Read More

  • December 2, 2016

  • Immuno-Oncology 360° in 60 seconds

    The Immuno-oncology 360° program provides a unique 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. IO360° will take place at The Roosevelt Hotel in New York City, February 1 – 3, 2017. For more […]

    The Immuno-oncology 360° program provides a unique 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. IO360° will take place at The Roosevelt Hotel in New York City, February 1 – 3, 2017. For more information, visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

        REGISTER NOW

    Read More

  • December 1, 2016

  • IO360 Speaking Faculty Launch Collaboration on Cancer Neoantigens

    Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) recently announced a major collaboration focused on cancer neoantigens to accelerate the discovery of personalized cancer immunotherapies. “We’re proud to join the Parker Institute in this collaboration, which demonstrates the vital role that nonprofits can play in bringing together stakeholders from across sectors to […]

    Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) recently announced a major collaboration focused on cancer neoantigens to accelerate the discovery of personalized cancer immunotherapies.

    “We’re prjillodonnell-tormey-blogramyibrahim-blogoud to join the Parker Institute in this collaboration, which demonstrates the vital role that nonprofits can play in bringing together stakeholders from across sectors to work alongside one another to advance the field of cancer immunotherapy,” said Jill O’Donnell-Tormey, PhD, IO360° speaker and Cancer Research Institute CEO and director of scientific affairs.

    Dr Ramy Ibrahim, Vice President and Head of R&D for the Parker Institute will be joining Dr Jill O’Donnell-Tormey at the 3rd annual Immuno-Oncology 360° (IO360°) conference where both deliver talks on trends and collaborations in the IO space.

    To read more on the collaboration, click here.

    For more information on Immuno-Oncology 360°, click here.

    Read More

  • September 20, 2016

  • IO360° Lead Advisor and Co-Chair, Dr Axel Hoos featured in Life Science Leader on GSK’s Oncology R&D Pipeline

    We are delighted to highlight the latest piece “Is Oncology Back at GSK? Did it Ever Leave?” printed in Life Science Leader featuring IO360° Lead Advisor/Co-Chair and GSK’s SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno-Oncology, Dr Axel Hoos, who delves into GSK’s diversified oncology R&D pipeline with a focus on immuno-oncology. Dr […]

    axelhoos2016-2

    Immuno-Oncology 360° Lead Advisor & Co-chair, Axel Hoos, MD, PhD, GSK

    We are delighted to highlight the latest piece “Is Oncology Back at GSK? Did it Ever Leave?” printed in Life Science Leader featuring IO360° Lead Advisor/Co-Chair and GSK’s SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno-Oncology, Dr Axel Hoos, who delves into GSK’s diversified oncology R&D pipeline with a focus on immuno-oncology.

    Dr Hoos will be co-chairing the Immuno-Oncology 360° (IO360°) program taking place February 1-3, 2017 in NYC. He will also be delivering a presentation on “Business Models for Complex Science” along with participating in two panels “Trend and Collaborations in the IO Space” and “Importance of KOLs in IO: Issues and Controversies.”

    To read the full article: [Download Here]

    For more information on IO360° visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • August 2, 2016

  • IO360° Keynote, Dr Carl June Featured in NYT’s Article on Setting the Body’s “Serial Killers” Loose on Cancer

    The New York Times continues to showcase stories on how cancer immunotherapy developments are transforming the way cancer is treated. Several of the Immuno-Oncology 360° (IO360°) speakers were profiled in yesterday’s article “Setting the Body’s ‘Serial Killers’ Loose on Cancer.” Featured was IO360° Keynote, Dr Carl June of University of Pennsylvania, who discussed his personal […]

    The New York Times continues to showcase stories on how cancer immunotherapy developments are transforming the way cancer is treated. Several of the Immuno-Oncology 360° (IO360°) speakers were profiled in yesterday’s article “Setting the Body’s ‘Serial Killers’ Loose on Cancer.”

    Carl-JuneFeatured was IO360° Keynote, Dr Carl June of University of Pennsylvania, who discussed his personal journey behind researching and developing CAR-T cells that has resulted in several cases of remission and even instances where the cancer has disappeared entirely. Mentioned in the article was 11-year old Emily Whitehead, the first child to receive CAR-T therapy and who is widely-know for her miraculous recovery from acute lymphoblastic leukemia after receiving the treatment from Dr June and his team at University of Pennsylvania. Emily and her parents attended IO360° this past year to share Emily’s experience with CAR-T therapy and her journey to leading a cancer free life.

    The New York Times also highlighted IO360° speakers Dr Arie Belldegrun, President and CEO, Kite Pharma and Dr Renier Brentjens, director of cellular therapeutics at Memorial Sloan Kettering Cancer Center.

    To read the full New York Times article visit:
    http://www.nytimes.com/2016/08/02/health/cancer-cell-therapy-immune-system.html?_r=0

    For more information on Immuno-Oncology 360° visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • August 1, 2016

  • NYT’s Cover Story on Harnessing the Immune System to Fight Cancer

    This past weekend, the New York Times cover story featured several patients who have participated in cancer immunotherapy clinical trials and profiled a number of the IO360 speakers. The article gives hope for the future of IO. Immuno-Oncology 360° speaker Dr Jedd Wolchok of Memorial Sloan Kettering Cancer Center commented that “this [immunotherapy] is a […]

    This past weekend, the New York Times cover story featured several patients who have participated in cancer immunotherapy clinical trials and profiled a number of the IO360 speakers. The article gives hope for the future of IO. Immuno-Oncology 360° speaker Dr Jedd Wolchok of Memorial Sloan Kettering Cancer Center commented that “this [immunotherapy] is a fundamental change in the way that we think about cancer therapy.”

    Screen Shot 2016-08-01 at 4.17.04 PM

    From the New York Times Article

    The article also features 2017 Immuno-Oncology 360° keynote speaker Dr James Allison of MD Anderson Cancer Center, who discusses the importance of the preclinical work using mouse models that displayed positive results of the antibody he developed to block the checkpoints and launch T-cells against cancer. The antibody, known now as BMS’ Yervoy was further developed for humans and was approved in 2011 to treat advanced melanoma.

    To read the full New York Times article visit: http://mobile.nytimes.com/2016/07/31/health/harnessing-the-immune-system-to-fight-cancer.html?_r=0

    For more information on Immuno-Oncology 360° visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • July 28, 2016

  • FDA Accepts Investigational New Drug Application for a Cancer Vaccine Developed by Neon Therapeutics

    We are pleased to hear Neon Therapeutics, founded by Immuno-Oncology 360° keynote and MD Anderson Immunology Chair, Dr James Allison, has received the FDA’s acceptance of their IND application for their lead cancer vaccine program NEO-PV-01.   Neon Therapeutics recently shared data this month at IO360°’s Rational Combinations conference in New York on how they […]

    We are pleased to hear Neon Therapeutics, founded by Immuno-Oncology 360° keynote and MD Anderson Immunology Chair, Dr James Allison, has received the FDA’s acceptance of their IND application for their lead cancer vaccine program NEO-PV-01.

    Dr. James P. Allison in his laboratory

    Dr James Allison, MD Anderson Immunology Chair and IO360° 2017 Keynote Speaker

     

    Neon Therapeutics recently shared data this month at IO360°’s Rational Combinations conference in New York on how they are developing further treatment modalities including next-generation vaccines and T-cell therapies targeting both personalized as well as shared neoantigens. The FDA’s acceptance of the IND enables Neon Therapeutics to initiate their first clinical trial investigating the combination of a NEO-PV-01 with BMS’ Nivolumab in advanced melanoma, NSCLC and bladder cancer. The trial is expected to begin this year.

    Dr James Allison will be delivering a keynote address on Immune Checkpoint Blockade in Cancer Therapies: New Insights and Opportunities for Cures at the 3rd Annual Immuno-Oncology 360° program taking place January 31- February 3rd, 2017 in NYC.

    To read the full press release: http://www.businesswire.com/news/home/20160729005446/en/Neon-Therapeutics-Announces-FDA-Acceptance-Investigational-Drug

    To learn more about the 3rd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • July 6, 2016

  • Dpharm Europe Speaker Alexander Masters on Crowd Funding Cancer Cures

    We are delighted to highlight the latest piece printed in the London Telegraph by DPharm Europe speaker, Alexander Masters on the latest in a new financial paradigm to help fight cancer. From the Telegraph: The first person in the world to receive the only crowd-funded cancer drug in history will be Jan Smørlung, a village […]

    Alexander Masters, Author, Campaigner and Co-Founder, iCancer.org.uk

    Alexander Masters & Craig Lipset at DPharm Europe

    We are delighted to highlight the latest piece printed in the London Telegraph by DPharm Europe speaker, Alexander Masters on the latest in a new financial paradigm to help fight cancer.

    From the Telegraph:

    The first person in the world to receive the only crowd-funded cancer drug in history will be Jan Smørlung, a village fire inspector, who doesn’t mind us pointing our camera lens at his groin. ‘Yes, thank you. I am happy to assist the world,’ he says.

    A plump, healthy-looking man with a fresh haircut, wearing a white T-shirt, he looks like someone who rows out into misty forest lakes to catch a fish for breakfast. He has two children, six grandchildren and not much time.

    For over a decade, Jan’s consultant, world famous clinician Kjell Öberg, has held back the inevitable with every treatment so far known to medicine, from chemotherapy to small radioactive balls dribbled into Jan’s blood.

    Continue Reading Here.

    Listen to Alexander’s Story on PharmaTalk Radio

    Craig Lipset, MBA, Head of Clinical Innovation, R&D, Pfizer speaks with Alexander Masters, Author, Medical Campaigner and Co-Founder, iCancer.org.uk on:

    • The story of the formation of iCancer.org.uk and the Oncolytic Virus Fund
    • An alternative way to make clinical trials more accessible
    • Ethical and moral issues
    • A possible disruptive and sustainable model for other neglected medicines

    Listen to the program here.

    Read More

  • May 16, 2016

  • EU Commission Approves the First and Only Immuno-Oncology Combination for Treatment of Advanced Melanoma

    Earlier this year, the FDA approved the combination of BMS’ ipilimumab (Yervoy) plus nivolumab (Opdivo) for metastatic melanoma and Europe soon followed with last weeks approval by the European Commission, making this combination Europe’s first and only approved combination of 2 immuno-oncology agents. We were delighted to have Dr Jedd Wolchok of Memorial Sloan Kettering […]

    Earlier this year, the FDA approved the combination of BMS’ ipilimumab (Yervoy) plus nivolumab (Opdivo) for metastatic melanoma and Europe soon followed with last weeks approval by the European Commission, making this combination Europe’s first and only approved combination of 2 immuno-oncology agents.
    Jedd_Kate

    Dr. Jedd Wolchok, MSCKK and Kate Woda, The Conference Forum

    We were delighted to have Dr Jedd Wolchok of Memorial Sloan Kettering Cancer Center present the most recent data regarding the Immuno-Immuno Combinations of Yervoy + Opdivo in Melanoma at the IO360° conference that took place in February in NYC. (For a copy of the slides from his session, see below)

    We look forward to addressing more on this topic at the Rational Combinations 360° conference, June 23-24 2016, NYC.

    To read the full article, click here.

    To access Dr Wolchok’s presentation from IO360°, click here.

    For more information about Rational Combinations 360° conference, see link below and utilize code BLOG10 for 10% off the registration, click here.

    Read More

  • April 6, 2016

  • Alternative Model to Transform a Funding Gap in Rare Disease Clinical Research: Neuroendocrine Cancer in the Pancreas

    Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised – by one wealthy individual primarily, in return for […]

    Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised – by one wealthy individual primarily, in return for being in the trial.

    Photo Mark Earthy www.earthyphotography.co.uk This image is protected by Copyright

    Craig Lipset interviewing Alexander Masters and Dr Magnus Essand at DPharm Europe

    At DPharm Europe, Pfizer’s Craig Lipset interviewed on stage Alexander Masters to share his innovative story. We are delighted to share the journey and the latest updates on PharmaTalk Radio. In this disruptive discussion, we address:

    • The remarkable story of the formation of iCancer.org.uk and the Oncolytic Virus Fund
    • An alternative way to make clinical trials more accessible
    • Ethical and moral issues
    • A possible disruptive and sustainable business model for other neglected medicines

    Listen to the show here.

    The next DPharm: Disruptive Innovations to Advance Clinical Trials event takes place September 20-21 in Boston. The DPharm Europe event is scheduled for early February 8-9, 2017 in London. For more information about these events or our Immuno-Oncology events (IO 360° and Rational Combinations 360°), visit www.theconferenceforum.org.

    Guest Host:
    Craig Lipset, MBA, Head of Clinical Innovation, R&D, Pfizer

    Guest:

    Alexander Masters, Author, Campaigner and Co-Founder, iCancer.org.uk

    Producer:
    Valerie Bowling, Executive Director, Conference Forum & Pharma Talk Radio

    Telegraph Article Referenced by Craig During the Program: It’s time to sell tickets for places on life-saving medical trials
    http://www.telegraph.co.uk/science/2016/04/05/its-time-to-sell-tickets-for-places-on-life-saving-medical-trial/

    Read More

  • March 30, 2016

  • Carl June, MD, Immuno-Oncology Pioneer Speaks with Valerie Bowling at IO360

    Conference Forum Executive Director, Valerie Bowling sat down with Immuno-Oncology pioneer, Dr Carl June, University of Pennsylvania at the IO360° conference. They covered a range of topics from how Dr June got involved in immuno-oncology when most scientists and oncologists did not focus on the space to current challenges and progress. Watch the interview below. […]

    Conference Forum Executive Director, Valerie Bowling sat down with Immuno-Oncology pioneer, Dr Carl June, University of Pennsylvania at the IO360° conference. They covered a range of topics from how Dr June got involved in immuno-oncology when most scientists and oncologists did not focus on the space to current challenges and progress. Watch the interview below.

    Dr June was one of the keynotes at the  IO360° conference where he gave an update on hematologic malignancies. For more information about the IO360° conference that was presented in February 2016, please click here.

    Carl June, MD, Director, Translational Research Program, Professor of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

    WhiteheadsDr Carl June with his first IO pediatric patient, Emily Whitehead and her parents Kari and Tom Whitehead

    The next scheduled conference in the Imunno-Oncology space is Rational Combinations 360° which will take place June 23-24,2016 in New York City.

    Read More

  • March 20, 2016

  • Mark Simon, Torreya Partners Discusses Business Aspects of Immuno-Oncology with Valerie Bowling, Conference Forum

    Valerie Bowling, Conference Forum sat down with Mark Simon to discuss the business aspects of Immuno-Oncology at the IO360° conference. Mark gives insights into the challenges of intellectual capital vs financial capital, prioritizing combinations, consolidation in the industry, the future of vaccines and more. Watch the full interview below. Mark Simon moderated our “sensational seven” […]

    Valerie Bowling, Conference Forum sat down with Mark Simon to discuss the business aspects of Immuno-Oncology at the IO360° conference. Mark gives insights into the challenges of intellectual capital vs financial capital, prioritizing combinations, consolidation in the industry, the future of vaccines and more.

    Watch the full interview below.

    Mark Simon moderated our “sensational seven” panel dedicated to business aspects of immuno-oncology at the IO360° conference, which took place in February 2016 in NYC. For more information about the IO360° conference, please click here.

     

    The next scheduled conference in the Imunno-Oncology space is Rational Combinations 360° which will take place June 23-24,2016 in New York City.

     

    Read More

  • January 26, 2016

  • IO360 Speaker Dr. Jedd Wolchok Leads Trial that Results in FDA Approval of Opdivo Plus Yervoy in Melanoma

    Earlier this week, the FDA approved the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) for metastatic melanoma. The FDA based the approval on results of the phase III CheckMate-067 trial, which compared nivolumab plus ipilimumab or nivolumab alone versus ipilimumab monotherapy. Dr. Jedd Wolchok is the principal investigator of the CheckMate-067 trial and will be […]

    Earlier this week, the FDA approved the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) for metastatic melanoma. The FDA based the approval on results of the phase III CheckMate-067 trial, which compared nivolumab plus ipilimumab or nivolumab alone versus ipilimumab monotherapy.

    Jedd_WolchokDr. Jedd Wolchok is the principal investigator of the CheckMate-067 trial and will be delivering a talk on this combination therapy for melanoma at the 2nd Annual Immuno-Oncology 360° conference February 2-3, 2016 in NYC.

    “The combination of two immuno-oncology treatments, nivolumab and ipilimumab, has been shown to provide these patients with a much needed improvement in progression-free survival and response rates,” said IO360° speaker and principal investigator in CheckMate-067, Dr. Jedd Wolchok of Memorial Sloan Kettering Cancer Center in a recent statement.


    Abstract:

    The FDA expanded the approval of nivolumab plus ipilimumab to include all patients with unresectable or metastatic melanoma, regardless of BRAF V600 mutational status. Until now, the combination only had been indicated for patients with BRAF V600 wild-type disease.Nivolumab (Opdivo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) is the only FDA-approved combination of immune checkpoint inhibitors.

    Read the full article: http://snip.ly/wRHV

    To learn more about the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • January 26, 2016

  • IO360° Speaker Dr. Carl June Launches New T-Cell Company, Tmunity Therapeutics

    Congratulations to Immuno-Oncology 360° speaker Dr. Carl June, Director of the Translational Research Program at the University of Pennsylvania who recently co-founded Tmunity Therapeutics, an organization that is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. “The creation of Tmunity is the culmination of […]

    Congratulations to Immuno-Oncology 360° speaker Dr. Carl June, Director of the Translational Research Program at the University of Pennsylvania who recently co-founded Tmunity Therapeutics, an organization that is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications.

    Dr. Carl June“The creation of Tmunity is the culmination of a more than decade-long commitment by Penn and our founding team to link basic and translational research with clinical trial investigation, and will ensure that we remain at the leading edge in advancing cell therapies for multiple diseases,” said Carl H. June, MD, co-founder and chief scientific advisor of Tmunity Therapeutics.

    Dr. Carl June will be chairing and delivering a talk on CAR-T data for hematologic malignancies at the 2nd Annual Immuno-Oncology 360° conference taking place February 2-3, 2016 in NYC.

     

    Abstract:
    PHILADELPHIA, Jan. 12, 2016 /PRNewswire-USNewswire/ — Tmunity Therapeutics today announced that it is raising $10 Million in equity financing from Penn Medicine, the academic medical center of the University of Pennsylvania (Penn), and Lilly Asia Ventures, a premier venture capital firm focused on making investments in the life sciences sector. The financing will represent the first capital investment for Penn Medicine in a company co-founded by Penn faculty and researchers. The proceeds of the financing will be used to develop novel products to unleash the immunological potential of T cells to treat a wide range of diseases. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo. The company is also developing proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. These will rapidly advance toward the clinic personalized next-generation engineered T cell immunotherapies for cancer, infectious diseases and autoimmune disease.

    Read the full press release here: http://snip.ly/Fs7D
    To learn more about the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • January 13, 2016

  • A Moonshot to Cure Cancer by Vice President Joe Biden

    We are pleased to hear the announcement that Vice President Biden will lead a new national mission to “moonshot” a cure for cancer. Below is his blog posting on what this will entail. Inspiring a New Generation to Defy the Bounds of Innovation: A Moonshot to Cure Cancer. Three months ago, I called for a […]

    Vice President Joe Biden - Immuno Oncology Blog We are pleased to hear the announcement that Vice President Biden will lead a new national mission to “moonshot” a cure for cancer. Below is his blog posting on what this will entail.

    Inspiring a New Generation to Defy the Bounds of Innovation: A Moonshot to Cure Cancer.

    Three months ago, I called for a “moonshot” to cure cancer.

     

    Tonight, the President tasked me with leading a new, national mission to get this done.

    It’s personal for me. But it’s also personal for nearly every American, and millions of people around the world. We all know someone who has had cancer, or is fighting to beat it. They’re our family, friends, and co-workers.

    If this disease has touched your life, I want to hear your story.

    Today, cancer is the leading cause of death worldwide. And that’s only expected to increase in the coming decades — unless we make more progress today.

    I know we can.

    From my own personal experience, I’ve learned that research and therapies are on the cusp of incredible breakthroughs. Just in the past four years, we’ve seen amazing advancements. And this is an inflection point.

    Over the course of the past few months, I’ve met with nearly 200 of the world’s top cancer physicians, researchers, and philanthropists.

    And the goal of this initiative — this “Moonshot” — is to seize this moment. To accelerate our efforts to progress towards a cure, and to unleash new discoveries and breakthroughs for other deadly diseases.

    The science is ready.

    Several cutting-edge areas of research and care — including cancer immunotherapy, genomics, and combination therapies — could be revolutionary. Innovations in data and technology offer the promise to speed research advances and improve care delivery.

    But the science, data, and research results are trapped in silos, preventing faster progress and greater reach to patients. It’s not just about developing game-changing treatments — it’s about delivering them to those who need them.

    Right now, only 5 percent of cancer patients in the U.S. end up in a clinical trial. Most aren’t given access to their own data. At the same time, community oncologists — who treat more than 75 percent of cancer patients — have more limited access to cutting-edge research and advances.

    So I plan to do two things.

    1.) Increase resources — both private and public — to fight cancer.

    2.) Break down silos and bring all the cancer fighters together — to work together, share information, and end cancer as we know it.

    And the goal of this initiative is simple — to double the rate of progress. To make a decade worth of advances in five years.

    Here’s how we can do it:

    Over the next year, I will lead a dedicated, combined effort by governments, private industry, researchers, physicians, patients, and philanthropies to target investment, coordinate across silos, and increase access to information for everyone in the cancer community.

    Here’s what that means: The Federal government will do everything it possibly can — through funding, targeted incentives, and increased private-sector coordination — to support research and enable progress.

    We’ll encourage leading cancer centers to reach unprecedented levels of cooperation, so we can learn more about this terrible disease and how to stop it in its tracks.

    Data and technology innovators can play a role in revolutionizing how medical and research data is shared and used to reach new breakthroughs.

    We will help the oncology community improve communication with doctors across the United States and around the world, so the same care provided to patients at the world’s best cancer centers is available to everyone who needs it.

    And we will ensure that the patient community is heard — so patients and their families are treated as partners in care, with access to their own data and the opportunity to contribute to research.

    And we’re getting started right away.

    This Friday, I’ll head to the Abramson Cancer Center at the University of Pennsylvania’s Perelman School of Medicine to talk to their physicians and researchers and continue this national dialogue.

    Next week, at the World Economic Forum in Davos, Switzerland, I’ll meet with a group of international experts to discuss the current state of cancer research and treatment, and opportunities to accelerate this fight.

    And later this month, I’ll convene and chair the first of several meetings with cabinet secretaries and heads of relevant agencies to discuss ways to improve Federal investment and support of cancer research and treatment.

    Fifty-five years ago, President John F. Kennedy stood before a joint session of Congress and said, “I believe we should go to the moon.”

    It was a call to humankind.

    And it inspired a generation of Americans — my generation — in pursuit of science and innovation, where they literally pushed the boundaries of what was possible.

    This is our moonshot.

    I know that we can help solidify a genuine global commitment to end cancer as we know it today — and inspire a new generation of scientists to pursue new discoveries and the bounds of human endeavor.

    That is the history of the journey of this country. If there’s one word that defines who we are as Americans, it’s “possibility.” And these are the moments when we show up.

    We must move forward, right now. I know we can.

    Read More

  • January 4, 2016

  • Measuring Immunotherapy’s Past Year

    2015 was another year of outperformance for cancer immunotherapy companies. As measured by the Loncar Cancer Immunotherapy Index, cancer immunotherapy stocks were up 19.2% in 2015 versus 11.4% for the Nasdaq Biotechnology Index. This is in stark contrast to the broader stock market, as the Standard and Poor’s 500 Index fell 0.7% in 2015, its […]

    2015 was another year of outperformance for cancer immunotherapy companies. As measured by the Loncar Cancer Immunotherapy Index, cancer immunotherapy stocks were up 19.2% in 2015 versus 11.4% for the Nasdaq Biotechnology Index. This is in stark contrast to the broader stock market, as the Standard and Poor’s 500 Index fell 0.7% in 2015, its worst year since the financial crisis . There are a few insights that the entire cancer immunotherapy field can take away from how these publicly-traded companies performed last year.

    loncar Immunotherapy Index

    1. Even in a tough market, there is still plenty of reward for innovation.

    Immunotherapy was the brightest star in one of the stock market’s only positive sectors. While there was a global slowdown in commodity and industrial sectors, investors have still shown a willingness to pay up for growth and innovation. That is a positive for areas of innovation like immunotherapy. The healthy appetite for immunotherapy is simultaneously seen in public companies and the venture capital and private equity markets.

    2. Regulatory successes from leaders have supported the field.

    We have not only seen speedy approvals for PD-1’s in melanoma, lung cancer, and kidney cancer, but bispecific technologies and the first oncolytic virus were also recently approved. Regardless of whether these end up being commercial successes, do not discount how much their approval has been an important signal to investors who continue supporting new technologies. When there is evidence of regulatory support and a real path to market for alternative therapies, fundraising is easier for the whole sector.

    3. Immunotherapy valuations will be highly affected by the political environment.

    As measured by the Loncar Index, cancer immunotherapy stocks initially declined 25% from their peak when Hillary Clinton issued her now infamous September tweet about cracking down on drug spending. Given how immunotherapy is an emerging field, future political events will have an outsized impact on its prospects. It is important that the political class ultimately makes a distinction between raising the prices on old drugs and ensuring future innovation for new therapies is still fostered. In the meantime, expect volatility.

    Guest Submission By: Brad Loncar

    You can learn more about how cancer immunotherapy stocks trade by following the Loncar Cancer Immunotherapy Index at www.LoncarIndex.com.

    Read More

  • December 23, 2015

  • Immuno-Oncology Drug Development: Challenges & Next Steps

    PharmaTalk Radio’s Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD, National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what’s currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically […]

    Axel Hoos, MD, PhD, GlaxoSmithKline speaking at the Inaugural IO360° Conference

    PharmaTalk Radio’s Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD, National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what’s currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically they address:

    • – Ipilumumab/Nivo/Pembro challenges
    • – What can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?
    • – Challenges with the following modalities: Checkpoints, Oncolytic Virus’, Adoptive T-Cells, Cancer Vaccines
    • – Blinitumumab
    • – The more interesting agents in late stage development now in immunotherapy and its promise
    • – Immune related adverse events
    • – Adoptive cellular therapies, what is the most promising?
    • – Will IO become backbone therapies for cancer?
    • – What’s the next set of assets that are going to come out?-
    • – What can we expect within the next year or two?

    Guests:

    James Gulley, MD, PhD
    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

    Axel Hoos, MD, PhD, VP, Oncology R&D, GlaxoSmithKline

    Listen to the show here: http://www.blogtalkradio.com/pharmatalk/2015/12/21/immuno-oncology-drug-development-challenges-next-stepshttp://www.blogtalkradio.com/pharmatalk/2015/12/21/immuno-oncology-drug-development-challenges-next-steps

    The Immuno-Oncology 360° conference is scheduled for February 2-3, 2016  at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.

    Read More

  • December 10, 2015

  • IO360° Speaker Dr. Edith Perez on The People Behind the Data

    Conference Forum speaker Dr. Edith Perez, VP and Head of BioOncology, US Medical Affairs for Genentech recently wrote a blog piece that discusses the value of patients and how their involvement in clinical trials can help further research and development. “The people behind the data – they are the true heroes helping us find the […]

    Conference Forum speaker Dr. Edith Perez, VP and Head of BioOncology, US Medical Affairs for Genentech recently wrote a blog piece that discusses the value of patients and how their involvement in clinical trials can help further research and development.

    Edith_Perez-1

    Dr. Edith Perez at Immuno-Oncology 360°


    The p
    eople behind the data – they are the true heroes helping us find the next cancer breakthrough.”

    – Edith Perez, MD, Genentech

    Dr. Perez joined us last year at our inaugural Immuno-Oncology 360° program to discuss clinical trial design and management for cancer immunotherapies.

    At that program, we featured a patient, Jamie Goldfarb, who had stage 4 melanoma and is now cancer free as a result of participating in an immunotherapy clinical trial. Jamie Goldfarb is now a patient advocate and helps provide a patient’s insight in clinical development and trial design.

    This correlates to Dr. Perez’ position on patient involvement in her recent post.

    Abstract: In my work in oncology over the past 25 years, I’ve had the privilege of being involved in both research and patient care. These two fields use strikingly different approaches to achieve the same overarching goal—fighting cancer. Research is a tedious process. First, we start in the lab. We test, we tweak, and sometimes we fail before moving forward. Patient care is just the opposite. There is no room for testing or trial and error. When peoples’ lives are at risk, we do everything we can to treat the disease quickly based on what we know and make it go away.

    But ultimately, research advances do not exist without people.

    Read the full blog here: snip.ly/xIkb

    By means of the 2nd Annual Immuno-Oncology 360° program, taking place February 2-3, 2016 in NYC, we will be helping advance research and development in the cancer immunotherapy space. The program combines business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology (IO) clinical trials and help revolutionize the way cancer is treated.

    To learn more about the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

     

     

    Read More

  • November 23, 2015

  • FDA Approves Immunotherapy Drug Opdivo to Treat Renal Cell Carcinoma

    Congratulations to BMS who not only received FDA priority review status last week for Nivolumab (Opdivo) for Renal Cell Carcinoma, but have received today, FDA approval for the immunotherapy drug to treat the common form of kidney cancer in adults. According to The National Cancer Institute, an estimated 61,560 new cases and 14,080 deaths resulted […]

    Congratulations to BMS who not only received FDA priority review status last week for Nivolumab (Opdivo) for Renal Cell Carcinoma, but have received today, FDA approval for the immunotherapy drug to treat the common form of kidney cancer in adults.

    According to The National Cancer Institute, an estimated 61,560 new cases and 14,080 deaths resulted from kidney and renal pelvis cancer in the US this year.

    The immunotherapy drug Opdivo provides an option for patients who have received prior anti-angiogenic therapy and has demonstrated increased survival rates in patients with the kidney disease.

    Lead author of the NEJM article on renal cell carcinoma, Dr RJ Motzer of Memorial Sloan Kettering, will be delivering an in-depth talk on the most current phase III data for Nivolumab (Opdivo) for Renal Cell Carcinoma at the 2nd Annual Immuno-Oncology 360° conference, taking place February 2-3, 2016 at The New York Academy of Medicine.

    To read the full article visit:
    http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473971.htm

    For more information on the 2nd Annual Immuno-Oncology 360° conference visit:
    http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • November 19, 2015

  • IO 360° Speaker RJ Motzer and BMS Featured in Article on FDA Granting Priority Review to Nivolumab for Renal Cell Carcinoma

    Congratulations to BMS on receiving priority review for Opdivo in renal cell carcinoma. Final approval for the application will be made by March 16, 2016. Immuno-Oncology 360° (IO360°) speaker and lead author of the NEJM article on renal cell carcinoma, Dr. RJ Motzer of Memorial Sloan Kettering Cancer Center comments on Nivolumab toxicity stating: “Nivolumab […]

    Congratulations to BMS on receiving priority review for Opdivo in renal cell carcinoma. Final approval for the application will be made by March 16, 2016.

    Immuno-Oncology 360° (IO360°) speaker and lead author of the NEJM article on renal cell carcinoma, Dr. RJ Motzer of Memorial Sloan Kettering Cancer Center comments on Nivolumab toxicity stating:

    Nivolumab showed a favorable toxicity profile, with fewer grade 3 or 4 adverse events compared to everolimus. One of the previous standouts for everolimus as a popular treatment in kidney cancer was its favorable safety profile, so showing an improvement in the safety profile compared to everolimus is really remarkable.”

    Robert_Motzer

    RJ Motzer, Memorial Sloan Kettering Cancer Center

    Dr. Motzer will be delivering an in depth talk on the most current phase III data for Nivolumab for Renal Cell Carcinoma at the 2nd Annual Immuno-Oncology 360° conference taking place February 2-3, 2016 at The New York Academy of Medicine, NYC

    To read the full article visit: http://www.onclive.com/web-exclusives/fda-grants-priority-review-to-nivolumab-for-renal-cell-carcinoma

    For more information on the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • November 19, 2015

  • Immuno-Oncology 360° Announces the Support of Key Partnerships to Present Multiple Views to Advance IO as a Standard of Cancer Treatment

    We are delighted to announce new partnerships with Cancer Research Institute (CRI), Society of Immunotherapy for Cancer (SITC) and The Association for Cancer Immunotherapy (CIMT) on the 2nd Annual Immuno-Oncology 360° (IO360°) Conference, taking place February 2-3, 2016 at The New York Academy of Medicine, NYC. The IO360° conference is the only conference combining the […]

    We are delighted to announce new partnerships with Cancer Research Institute (CRI), Society of Immunotherapy for Cancer (SITC) and The Association for Cancer Immunotherapy (CIMT) on the 2nd Annual Immuno-Oncology 360° (IO360°) Conference, taking place February 2-3, 2016 at The New York Academy of Medicine, NYC.

    The IO360° conference is the only conference combining the most current business, clinical and scientific developments to help accelerate clinical trials and FDA approval in the growing space of cancer immunotherapies.

    With the support of CRI, SITC and CIMT, the Immuno-Oncology 360° program will help drive the field of cancer immunotherapy through knowledge sharing and disseminating the most current data, innovative approaches and developments that are changing the way cancer is treated.

    For more information regarding Immuno-Oncology 360° visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • November 12, 2015

  • How Patient Research Changed the Way We Present Clinical Trial Conferences

    Valerie Bowling, Executive Director of The Conference Forum discusses how her research with patients changed the way she looks at and presents all clinical trials conferences. ____________________________________________________ Five years ago, Greg Simon, who was the Head of Policy at Pfizer at the time and is now CEO of Poliwogg, asked our DPharm audience when was […]

    GregSimon-1

    Greg Simon, CEO, Poliwogg challenging the first Dpharm audience.

    Valerie Bowling, Executive Director of The Conference Forum discusses how her research with patients changed the way she looks at and presents all clinical trials conferences.
    ____________________________________________________
    Five years ago, Greg Simon, who was the Head of Policy at Pfizer at the time and is now CEO of Poliwogg, asked our DPharm audience when was the last time you thanked your patients for being in a clinical trial. No one raised their hand. My immediate thought was that there was an urgent need for a conference on customer service for patients in clinical trials.

    JeriC

    Graphic illustration of Jeri Burtchell, Founder of PatientsinResearch.org and our first patient speaker!

    I began to research the topic within the pharmaceutical industry and received enlightening feedback: we can’t look at patients as customers, we can’t directly communicate with patients, there are privacy laws, we don’t directly work with patients, and more. I learned that often people who have direct contact with patients are not necessarily trained to work with patients to empathize with their condition and life style.

     

    What To Do?
    I knew that something drastically had to change and a paradigm shift in how the industry views and works with patients was paramount. I also realized that as a researcher, I needed to start with myself. I needed to make that paradigm shift in who and how I do research. With that, five years ago, for the first time I began to research directly with patients. Getting their feedback changed the way I produce conferences and, more importantly, how I can potentially affect positive change for patients through my conferences.

     

    What Patient Research Taught Me
    Patients taught me empathy with their disease, but also with their lifestyle and their struggles in finding and experiencing a clinical trial. In particular, I learned the vital need to cover sessions that:

    1. Understand and incorporate the patient’s voice in designing clinical trials and developing a clinical endpoint

    2. Vastly improve the patient’s entire experience in a clinical trial

    Patient Advocate Speakers

     

    Dpharm US, Dpharm Europe, Patients as Partners, and Immuno-Oncology 360 would not be possible without the many supportive patients and industry executives who helped my team and I gain a better understanding of the science of patient-centricity in clinical research. Thank you!

    Read More

  • November 10, 2015

  • Safety Elements of Cancer Immunotherapies Featured on Pharma Talk Radio

    In this episode of Pharma Talk Radio, we feature medical oncologist, Dr Anna Pavlick, Director of the Melanoma Program at the NYU Cancer Institute on Safety Elements of Cancer Immunotherapies. Dr Pavlick originally gave this presentation in June 2015 at the IO360 conference. We are pleased to bring this session to the public to help […]

    IOsqIn this episode of Pharma Talk Radio, we feature medical oncologist, Dr Anna Pavlick, Director of the Melanoma Program at the NYU Cancer Institute on Safety Elements of Cancer Immunotherapies. Dr Pavlick originally gave this presentation in June 2015 at the IO360 conference. We are pleased to bring this session to the public to help researchers, doctors, patients and care givers with some information on immune related adverse affects of immuno therapy.

    Listen to the episode here.

    The next IO360 conference will take place February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, visit is www.theconferenceforum.org

     

    Read More

  • September 28, 2015

  • Penn Medicine Immunotherapy Pioneer Carl June, MD, To Deliver Keynote On CAR-T Therapy For Hematologic Malignancies at IO360° Conference February 2016 in New York City

    University of Pennsylvania cancer immunology expert, Carl June, MD, is scheduled to keynote on CAR-T data for Hematologic Malignancies at the 2nd Annual Immuno-Oncology 360° (IO360°) program taking place February 2-3, 2016 at The New York Academy of Medicine, NY. Dr. June has recently been named one of the two recipients for the 2015 Paul […]

    University of Pennsylvania cancer immunology expert, Carl June, MD, is scheduled to keynote on CAR-T data for Hematologic Malignancies at the 2nd Annual Immuno-Oncology 360° (IO360°) program taking place February 2-3, 2016 at The New York Academy of Medicine, NY.

    Dr. Carl JuneDr. June has recently been named one of the two recipients for the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy. The prize is awarded to scientists who have made great advancements in the field which Paul Ehrlich worked including cancer research, immunology, microbiology and chemotherapy. Dr. June is largely recognized as the leader of the team responsible for the first successful and sustained demonstration of the use of CAR-T cell therapy.*

    The 2nd Annual IO360° program, developed with key advisors Axel Hoos, MD, PhD, GSK and James Gulley, MD, PhD, NCI, will provide a 360° perspective on the intricacies in the business deals and clinical trial strategies with scientific data to revolutionize the way cancer is treated.

    The program will also include a keynote talk from Jedd Wolchok, MD, PhD, Chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center along with additional talks by key leaders in the IO space.

    “We are honored to welcome Dr. June to IO360° as one of the pioneering leaders in the Immuno-Oncology space. His dedication to advancing therapies for patients raises the bar for the entire industry,” said Kate Woda, Conference Director, IO360°.

    Other confirmed speakers include:

    • – Anne Altmeyer, PhD, MBA, MPH, VP, Business Development & Licensing, Head Negotiations, Oncology, Novartis
    • – Roy Baynes, MD, PhD, SVP, Global Clinical Development, Merck Research Labs
    • – Kenneth Bloom, MD, FACP, Chief Medical Officer, GE Healthcare
    • – Mark Frohlich, MD, EVP, Development and Portfolio Management, Juno Therapeutics
    • – Winald Gerritsen, MD, PhD, Professor and Medical Oncologist, Radboud Medical Center
    • – Robert Glassman, MD, Vice Chairman, Global Healthcare Investment Banking, Credit Suisse and Clinical Assistant Professor, Division of Hematology-Oncology, Weill-Cornell Medical School
    • – Omid Hamid, MD, Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute
    • – Ramy Ibrahim, MD, Clinical VP of Immuno-Oncology, AstraZeneca
    • – Michael Kalos, PhD, CSO, Cancer Immunobiology, Eli Lilly
    • – Howard Kaufman, MD, FACS, Chief Surgical Officer, Assoc. Director, Rutgers Cancer Institute of NJ
    • – Ira Klein, MD, MBA, FACP, National Medical Director, Clinical Thought Leader, Office of the CMO, Aetna
    • – Michael King Jr. Managing Director and Senior Biotech Analyst, JMP Securities
    • – Philippe Lopes-Fernandes, SVP and Head of Global Licensing & Business Development, EMD Serono
    • – Ian McCaffery, PhD, Head, Companion Diagnostics, Oncology Biomarker Development, Genentech
    • – Andrea Perrone, MD, Head of Clinical Imaging, Translational Medicine, Merck
    • – David Reese, MD, SVP, Translational Sciences, Amgen
    • – Leonard Saltz, MD, Chief, Gastrointestinal Oncology Service and Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center
    • – Mark Simon, MBA, Partner, Torreya Partners
    • – Jeffrey Weber, MD, PhD, Senior Member and Director Donald A Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center

    For more information about the Immuno-Oncology 360° program, visit http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    About The Conference Forum:
    The Conference Forum develops specialized programs and events for professionals in the life science and healthcare industries. They currently offer conferences for R&D leaders, clinical development professionals, biotech executives, VCs, drug delivery specialists and patient advocates. Their mission is to create the best content, exchange ideas and solutions among peers and provide quality networking for Pharmaceutical and Biotech professionals. http://www.theconferenceforum.org

    *Penn Medicine Press Release, March 2015

    Read More

  • June 17, 2015

  • CRI Member to Chair Immuno-Oncology 360 Conference

    Originally published by the Cancer Research Institute: We’re pleased to share that Axel Hoos, M.D., Ph.D., a member of the CRI Scientific Advisory Council, co-director of our Cancer Immunotherapy Consortium Leadership Committee, and vice president for oncology research and development at GlaxoSmithKline, will be the chair and industry keynote for the Immuno-Oncology 360° Conference, which […]

    Originally published by the Cancer Research Institute:

    We’re pleased to share that Axel Hoos, M.D., Ph.D., a member of the CRI Scientific Advisory Council, co-director of our Cancer Immunotherapy Consortium Leadership Committee, and vice president for oncology research and development at GlaxoSmithKline, will be the chair and industry keynote for the Immuno-Oncology 360° Conference, which will be held on June 29-30, 2015, at the Faculty House at Columbia University in New York, NY.

    Over the past five years, the FDA has approved four new immunotherapies for prostate cancer, melanoma, and lung cancer, and more are going to come in the next five years. These include drugs like checkpoint inhibitors, chimeric antigen receptor (CAR) T cell therapies, cancer vaccines, and immune modulators, and combinations will be a key component. With the growth of cancer immunotherapy drug development on the rise, the approaches for business are undergoing a rapid change to keep up. The Immuno-Oncology 360° Conference will bring together business and clinical development strategies, as well as scientific updates, to accelerate clinical trials and FDA approval in the growing space of cancer immunotherapies.

    “We are undergoing a radical change in cancer treatment, and the biopharma industry needs to gain information that will be beneficial for industry and patients,” said Axel Hoos, M.D., Ph.D. “The conference will deal with a panoply of topics, including the investment landscape and key business deals, combination immunotherapies and how to test them in clinical trials, and what role the patient can have on clinical designs and recruitment procedures.”

    Axel Hoos, M.D., Ph.D., will give the keynote address, titled “The Future of Immuno-Oncology,” on June 30.

    Learn more at www.theconferenceforum.org/conferences/immuno-oncology-360/overview.

    Read More

  • June 5, 2015

  • National Cancer Institute and Merck Research Labs Guests on Pharma Talk Radio Discussing the Exciting Potential and Challenges with Immuno-Oncology

    Immuno-Oncology is arguably the most exciting area in the advancement of science and patient care today.  However, with all research, there are plenty of challenges and to get a better understanding of this innovative approach to cancer research, we were pleased to welcome to Pharma Talk Radio, James Gulley, MD, PhD of the National Cancer […]

    Immuno-Oncology is arguably the most exciting area in the advancement of science and patient care today.  However, with all research, there are plenty of challenges and to get a better understanding of this innovative approach to cancer research, we were pleased to welcome to Pharma Talk Radio, James Gulley, MD, PhD of the National Cancer Institute and Roy Baynes, MD, PhD at Merck Research Labs. Joining Drs Gulley and Baynes was Kate Woda, Director of the IO360 conference taking place at Columbia University Faculty House on June 29-30 in NYC.

    Valerie Bowling, Conference Director, CMOW SummitHost:
    Valerie Bowling, Producer, Pharma Talk Radio

     

     

    Guests:
    James Gulley BWJames Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

     

    Roy Baynes B&WRoy Baynes, MD, PhD, Senior Vice President, Global Clinical Development, Merck Research Labs

     

     

    Kate Woda B&WKate Woda, Director, IO 360

     

     

     

    Listen to the Episode: http://www.blogtalkradio.com/pharmatalk/2015/06/04/immuno-oncology-exploring-the-challenges-potential

    For more details on Immuno-Oncology 360 visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

    Read More

  • May 13, 2015

  • Congratulations to Keynote Stéphane Bancel and Moderna for their #1 Disruptive Ranking by CNBC

    Congratulations to Moderna’s Stephane Bancel, our PODD 2015 keynote and Dr Tal Zaks, featured speaker at Immuno-Oncology 360° for leading the #1 ranked disruptive company according to CNBC. “The third annual Disruptor 50 list, CNBC features private companies in 16 industries—from aerospace to financial services to cybersecurity to retail—whose innovations are revolutionizing the business landscape. […]

    Congratulations to Moderna’s Stephane Bancel, our PODD 2015 keynote and Dr Tal Zaks, featured speaker at Immuno-Oncology 360° for leading the #1 ranked disruptive company according to CNBC.

    “The third annual Disruptor 50 list, CNBC features private companies in 16 industries—from aerospace to financial services to cybersecurity to retail—whose innovations are revolutionizing the business landscape. These forward-thinking upstarts have identified unexploited niches in the marketplace that have the potential to become billion-dollar businesses, and they rushed to fill them. In the process, they are creating new ecosystems for their products and services. ”

    moderna_bancel*150

    Stéphane Bancel, President and Founding CEO, Moderna Therapeutics

    President and Founding CEO, Stéphane Bancel will keynote the 2015 Partnership Opportunities in Drug Delivery Conference. Stéphane joined Moderna in the summer of 2011 when it was a one employee and one patent company, after Dr. Noubar Afeyan and the board described to him the technology behind messenger RNA Therapeutics™. He has assembled a world-class team and raised the company’s financing. Stéphane is named as an inventor on over 45 patent filings in the field of messenger RNA technology. These filings include claims covering a broad range of novel compositions and formulations as well as manufacturing and clinical methods in the fields of human and animal therapeutics, diagnostics and cell processing.

    zaks

    Tal Zaks, MD, PhD, C​hief Medical Officer, Moderna Therapeutics

     

     

    Tal Zaks, MD, PhD, C​hief Medical Officer will address the IO Investment Landscape and Business Perspective at the 1st annual At Immuno-Oncology 360° along with Michael Schmidt, PhD, Director, Biotechnology, Leerink Partners, Mark Simon, Partner, Torreya Partners, and Robert Stein, MD, PhD, Chief Science Officer, Agenus, Inc.

    Read More